Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

NCT00411905 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT00411905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00411905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 1/2
Overall status
Completed
Start date
June 1, 2006
Completion date
August 1, 2011
Enrollment
45 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes